John Asheld, DO
Nuclear Cardiology · West Islip, NYNPI 1699935973
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $19,500 of the $23,922 with a category attached, or 81.5%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 86.8% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2019 at $9,914 and has fallen 96.6% since, to $333 in 2025. Among nuclear cardiology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 122 payments — averaging $196.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$21K
- Abbott$1K
- Novartis$361
- Boston Scientific$306
- Abiomed$264
- Astellas Pharma US Inc$180
- plus $547 from 11 others
What the payments were for
- Speaking & faculty fees$19,50082%
- Food & beverage$4,22318%
- Education$1991%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 47 | $20,770 |
| Abbott | 25 | $1,495 |
| Novartis | 17 | $361 |
| Boston Scientific | 11 | $306 |
| Abiomed | 2 | $264 |
| Astellas Pharma US Inc | 2 | $180 |
| Edwards Lifesciences | 2 | $151 |
| Esperion Therapeutics, Inc. | 1 | $109 |
| Johnson & Johnson | 5 | $78 |
| Kestra Medical Technology Services, Inc. | 1 | $55 |
| E.r. Squibb & Sons, L.L.C. | 2 | $34 |
| Amgen | 2 | $32 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Medtronic | 1 | $21 |
| Boehringer Ingelheim | 1 | $19 |
| Merck | 1 | $17 |
| Bardy Diagnostics, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$19,615
- CARDIOMEMS$345
- Impella$264
- CardioMEMS HF System$239
- OPTIS$176
- Confirm Rx$165
- Allure CRT Pacemaker$128
- NEXLIZET$109
- NEXLETOL$109
- WATCHMAN Access System$108
How this compares
$23,922 in reported general payments places this provider in the 90th percentile of 21 nuclear cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 63 | $96,571 |
| JardianceEmpagliflozin | 40 | $54,302 |
| Repatha SureclickEvolocumab | 12 | $19,208 |
| Metoprolol Succinate | 152 | $2,080 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 29 | $1,800 |
| Atorvastatin Calcium | 165 | $1,650 |
| Valsartan | 49 | $1,314 |
| Nifedipine ErNifedipine | 17 | $704 |
| Amiodarone Hcl | 18 | $585 |
| Losartan Potassium | 43 | $355 |
| Amlodipine Besylate | 86 | $352 |
| ClopidogrelClopidogrel Bisulfate | 32 | $324 |
| Rosuvastatin Calcium | 26 | $275 |
| Lisinopril | 42 | $227 |
| Bumetanide | 11 | $217 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $19 | $54,30240 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 21 nuclear cardiology providers in New York.
Other nuclear cardiology in West Islip
- Wilbur AsheldWest Islip$11K
- Klaus RentropNew York$5.6M
- Diwakar JainHawthorne$105K
- Brian RiegelWilliamsville$23K
- Jonathan WeinsaftNew York$10K
- Ossama SamuelBrooklyn$7K
- Rajesh RohatgiGarden City$4K
- Harout YacoubNew York$2K
- Nicholas PapapietroBrooklyn$2K
- Ahmad Nawid LatifiRochester$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.